October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

by | Nov 5, 2021

Top Biopharma Partnership by Upfront Cash and Equity

October 2021

Xencor development and commercialization deal with Janssen for plamotamab and XmAb bispecific antibodies

Announced: October 4, 2021

Total Deal Value: $1,313M

Upfront Cash: $100M

Upfront Equity: $25M

Option Payments: n/a

Milestones: $1,188M (Dev., Reg., and Sales)

Royalty: Tiered mid-teen to low-twenties

Cost and Profit Split: n/a

The Asset:

Phase I plamotamab, its CD20 x CD3 XmAb bispecific antibody as a monotherapy or in combination regimens, and new XmAb B-cell targeting bispecific antibodies for the treatment of CD20-expressing hematologic malignancies.

Deal Structure:

Development and Commercial License

Partnership Features:

Co-Development and co-promotion option to add compounds.

The Details:

  • Xencor granted Janssen exclusive, worldwide rights to develop and commercialize plamotamab, its CD20 x CD3 XmAb bispecific antibody as a monotherapy or in combination regimens, and new XmAb B-cell targeting bispecific antibodies for the treatment of CD20-expressing hematologic malignancies.
  • Janssen will pay 80% of costs and Xencor 20%.
  • Additionally, Xencor and Janssen signed a two-year research partnership to discover XmAb CD28 bispecific antibody applicants against B-cell targets by utilizing Xencor’s XmAb bispecific Fc technology while Janssen has an exclusive worldwide option to license and develop selected molecules in combination with plamotamab and other agents.
  • Xencor has the option to co-fund development costs in return for higher royalties and co-detailing rights for such products in the US.
  • Xencor will receive $100M in upfront cash, $25M in upfront equity investment, and is eligible for up to $1.19B in development, regulatory, and sales milestones, plus tiered mid-teen to low-twenties royalties.

Last Month:

The Deal of the Month for September 2021 was REGENXBIO and AbbVie’s deal with $370M up front for RGX-314. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

25,544

Deal Profiles

15,147

Funding Rounds

28,034

Company Profiles

17,936

Product Profiles

119K+

Clinical Trials

3,982

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals amended their 2015 deal to develop and commercialize gene editing therapies. This expansion is for Phase I/II CTX001 for severe sickle cell diseases and transfusion-dependent beta-thalassemia. CRISPR will receive $900M up front, up to $200M in milestones upon the first regulatory approval, and a cost/profit split of 40%.

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant in Phase III for advanced squamous cell carcinoma of the head and neck. Debiopharm will receive EUR188M ($227M) up front and is eligible for up to EUR710M ($856M) in milestones, plus royalties. This was the largest upfront cash and equity for a partnership signed in March 2021.

Biotech and Pharma Deals in 2020

Biotech and Pharma Deals in 2020

Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.

Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.